Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study

NCT06202625 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06202625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06202625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study
Lead sponsor
Peking University People's Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 13, 2024
Completion date
October 30, 2025
Enrollment
142 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

stem cell transplant complications, thrombocytopenia